Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 17:05 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
August 29, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter...
Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022
August 25, 2022 16:05 ET
|
Daxor Corporation
Conference Call to be held today at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology,...
Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
August 24, 2022 16:40 ET
|
Daxor Corporation
Conference Call to be held on the same day at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
July 27, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, July 27, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today an unaudited increase of 49.4% in sales of...
DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
July 21, 2022 08:00 ET
|
Daxor Corporation
Daxor Has Exclusive Access to the Cardiovascular Industry's Most Comprehensive and Powerful Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically...
DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE
July 18, 2022 08:00 ET
|
Daxor Corporation
Company Received Funding from NIH to Accelerate New Clinical Decision Support Software For Use With Daxor’s Blood Volume Analyzer for Heart Failure Treatment Oak Ridge, TN, July 18, 2022 (GLOBE...
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE
June 27, 2022 08:00 ET
|
Daxor Corporation
New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer Oak Ridge, TN, June ...
Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting
June 13, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, June 13, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American...
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
May 25, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of...